RxDoctor Payments Data

Molly Engelkes

Gerontology · Rockford, ILNPI 1639542657

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Lilly USA, LLC at 45.7% of the total.

$431in general payments, 2019–2025

Across 13 payments — averaging $33.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$197
  • Abbott$52
  • Bayer$47
  • Novo Nordisk$38
  • Ardelyx, Inc.$32
  • Novartis$25
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431 in reported general payments places this provider in the 65th percentile of 180 gerontology providers in Illinois.

See all gerontology providers in Illinois

Medicare billing

Part B allowed, 2024
$76,367
Medicare patients
116
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$108,020
OtezlaApremilast13$64,615
XareltoRivaroxaban60$36,508
MounjaroTirzepatide27$35,310
JardianceEmpagliflozin28$34,318
Tresiba Flextouch U-200Insulin Degludec27$31,891
TrulicityDulaglutide30$30,158
BriviactBrivaracetam12$16,511
MyrbetriqMirabegron33$15,832
FarxigaDapagliflozin Propanediol25$15,471
Tresiba Flextouch U-100Insulin Degludec29$13,510
RybelsusSemaglutide12$11,095
GemtesaVibegron17$10,296
SymbicortBudesonide/Formoterol Fumarate15$7,698
Fentanyl54$7,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$197$65,46957 claims
AstraZenecaFarxiga, Symbicort, Brilinta$18$28,99152 claims
Novo NordiskRybelsus$38$11,09512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 180 gerontology providers in Illinois.

Other gerontology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →